The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Passive targeting of nanoparticles to cancer: A comprehensive review of the literature
Open accessAbstract
Cancer remains the one of the most common causes of mortality in humans; thus, cancer treatment is currently a major focus of investigation. Researchers worldwide have been searching for the optimal treatment (the 'magic bullet') that will selectively target cancer, without afflicting significant morbidity. Recent advances in cancer nanotechnology have raised exciting opportunities for specific drug delivery by an emerging class of nanotherapeutics that may be targeted to neoplastic cells, thereby offering a major advantage over conventional chemotherapeutic agents. There are two ways by which targeting of nanoparticles may be achieved, namely passive and active targeting. The aim of this study was to provide a comprehensive review of the literature focusing on passive targeting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Fang, J., Nakamura, H., & Maeda, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,559
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
Therapeutic Nanoparticles for Drug Delivery in Cancer
Cho, K., Wang, X., Nie, S., Chen, Z. (., & Shin, D. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1441 · Cited by 2,920
Nanoparticle-based targeted drug delivery
Singh, R., & Lillard, J. W. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2008.12.004 · Cited by 2,734
Maeda, H. (2001) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(00)00013-3 · Cited by 2,495
Exploiting the enhanced permeability and retention effect for tumor targeting
Iyer, A. K., Khaled, G., Fang, J., & Maeda, H. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.07.005 · Cited by 1,846
Active targeting schemes for nanoparticle systems in cancer therapeutics
Byrne, J. D., Betancourt, T., & Brannon-Peppas, L. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.08.005 · Cited by 1,731
Changing views of the role of matrix metalloproteinases in metastasis
Chambers, A. F., & Matrisian, L. M. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.17.1260 · Cited by 1,588
Papapetropoulos, A., García-Cardeña, G., Madri, J. A., & Sessa, W. C. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119868 · Cited by 1,191
Targeting nanoparticles to cancer
Wang, M., & Thanou, M. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.03.005 · Cited by 931
Enhanced Permeability and Retention (EPR) Effect for Anticancer Nanomedicine Drug Targeting
Greish, K. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-609-2_3 · Cited by 841
Greish, K. (2007) · Journal of Drug Targeting · doi:10.1080/10611860701539584 · Cited by 600
Passive and Active Drug Targeting: Drug Delivery to Tumors as an Example
Torchilin, V. P. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00477-3_1 · Cited by 573
Nanoparticles—a historical perspective
KREUTER, J. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.10.021 · Cited by 540
Maeda, H., Fang, J., Inutsuka, T., & Kitamoto, Y. (2003) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00271-0 · Cited by 537
Okamoto, T., Akaike, T., Sawa, T., Miyamoto, Y., van der Vliet, A., & Maeda, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102417200 · Cited by 468
MAEDA, H. (2012) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.88.53 · Cited by 291
(1981) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/67.3.663 · Cited by 268
Advances of Cancer Therapy by Nanotechnology
Wang, X., Wang, Y., Chen, Z. G., & Shin, D. M. (2009) · Cancer Research and Treatment · doi:10.4143/crt.2009.41.1.1 · Cited by 230
Maeda, H., Noguchi, Y., Sato, K., & Akaike, T. (1994) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1994.tb02362.x · Cited by 221
Wu, J., Akaike, T., & Maeda, H. (1998) · PubMed · Cited by 212
Metalloproteinases in tumor progression: the contribution of MMP-9.
Himelstein, B. P., Cañete-Soler, R., Bernhard, E. J., Dw, D., & Muschel, R. J. (1995) · PubMed · Cited by 210
Dephosphorylation of Endothelial Nitric-oxide Synthase by Vascular Endothelial Growth Factor
Kou, R., Greif, D., & Michel, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204519200 · Cited by 192
Microvascular architecture of experimental colon tumors in the rat.
Skinner, S. A., Tutton, P. J. M., & O’Brien, P. E. (1990) · PubMed · Cited by 180
Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application
Seki, T., Fang, J., & Maeda, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01323.x · Cited by 179
Yasuda, H., Yamaya, M., Nakayama, K., Sasaki, T., Ebihara, S., Kanda, A., Asada, M., Inoue, D., Suzuki, T., Okazaki, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.0436 · Cited by 170
The Rise and Rise of Stealth Nanocarriers for Cancer Therapy: Passive Versus Active Targeting
Huynh, N. T., Roger, E., Lautram, N., Benoît, J.-P., & Passirani, C. (2010) · Nanomedicine · doi:10.2217/nnm.10.113 · Cited by 164
Involvement of the Kinin‐generating Cascade in Enhanced Vascular Permeability in Tumor Tissue
Matsumura, Y., Kimura, M., Yamamoto, T., & Maeda, H. (1988) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1988.tb01563.x · Cited by 163
Enhanced Vascular Permeability in Solid Tumor Involving Peroxynitrite and Matrix Metalloproteinases
Wu, J., Akaike, T., Hayashida, K., Okamoto, T., Okuyama, A., & Maeda, H. (2001) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2001.tb01114.x · Cited by 161
MAEDA, H., Takeshita, J., & Kanamaru, R. (1979) · International journal of peptide & protein research · doi:10.1111/j.1399-3011.1979.tb01730.x · Cited by 159
Yasuda, H., Nakayama, K., Watanabe, M., Suzuki, S., Fuji, H., Okinaga, S., Kanda, A., Zayasu, K., Sasaki, T., Asada, M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1124 · Cited by 120
Targeting of nanoparticles in cancer
Talekar, M., Kendall, J. D., Denny, W. A., & Garg, S. (2011) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32834a4554 · Cited by 115
Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues
Wu, J., Akaike, T., Hayashida, K., Miyamoto, Y., Nakagawa, T., Miyakawa, K., Müller‐Esterl, W., & Maeda, H. (2001) · International Journal of Cancer · doi:10.1002/ijc.10142 · Cited by 109
Siemens, D. R., Heaton, J. P. W., Adams, M. A., Kawakami, J., & Graham, C. H. (2009) · Urology · doi:10.1016/j.urology.2009.03.004 · Cited by 100
Li, C. J., Miyamoto, Y., Kojima, Y., & Maeda, H. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.179 · Cited by 96
Pharmaceutical Perspectives of Cancer Therapeutics
Lu, Y. W., & Mahato, R. I. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0131-6 · Cited by 93
Kallikrein and Kinin Receptor Expression in Inflammation and Cancer
Bhoola, K. D., Ramsaroop, R., Plendl, J., Cassim, B., Dlamini, Z., & Naicker, S. (2001) · Biological Chemistry · doi:10.1515/bc.2001.013 · Cited by 87
Kallikrein–kinin in infection and cancer
Maeda, H., Wu, J., Okamoto, T., Maruo, K., & Akaike, T. (1999) · Immunopharmacology · doi:10.1016/s0162-3109(99)00104-6 · Cited by 83
Protein tailoring for food and medical uses
Williams, A. P. (1987) · Food Chemistry · doi:10.1016/0308-8146(87)90170-1 · Cited by 76
Protein tailoring for food and medical uses
Feeney, R. E., & Whitaker, J. R. (1986) · M. Dekker eBooks · Cited by 64
Maeda, H. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.002 · Cited by 64
Tanaka, S., Akaike, T., Wu, J., Fang, J. Q., Sawa, T., Ogawa, M., Beppu, T., & Maeda, H. (2003) · Journal of drug targeting · doi:10.1080/1061186031000086072 · Cited by 59
Cancer Detection and Treatment: The Role of Nanomedicines
LaRocque, J., Bharali, D. J., & Mousa, S. A. (2009) · Molecular Biotechnology · doi:10.1007/s12033-009-9161-0 · Cited by 58
Hori, K., Saito, S., Takahashi, H., Sato, H., Maeda, H., & Sato, Y. (2000) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2000.tb00940.x · Cited by 45
Seki, T., Fang, J. Q., & Maeda, H. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0131-6_3 · Cited by 33
Noguchi, A., Takahashi, T., Yamaguchi, T., Kitamura, K., Noguchi, A., Tsurumi, H., Takashina, K., & Maeda, H. (1992) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1992.tb00093.x · Cited by 32
(1989) · PubMed
Cited by
Ferroptosis, a new form of cell death: opportunities and challenges in cancer
Mou, Y., Wang, J., Wu, J., He, D., Zhang, C., Duan, C., & Li, B. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0720-y · Cited by 1,930
Emerging Strategies of Cancer Therapy Based on Ferroptosis
Shen, Z., Song, J., Yung, B. C., Zhou, Z., Wu, A., & Chen, X. (2018) · Advanced Materials · doi:10.1002/adma.201704007 · Cited by 740
Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors
Gagliardi, A., Giuliano, E., Venkateswararao, E., Fresta, M., Bulotta, S., Awasthi, V., & Cosco, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.601626 · Cited by 571
Vankayala, R., & Hwang, K. C. (2018) · Advanced Materials · doi:10.1002/adma.201706320 · Cited by 557
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
Obidiro, O., Battogtokh, G., & Akala, E. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071796 · Cited by 511
Metadata
- Authors
- BAZAK, R., HOURI, M., ACHY, S. E., HUSSEIN, W., & REFAAT, T.
- Venue
- Molecular and Clinical Oncology
- Publisher
- Spandidos Publications
- Published
- 2014-07-23
- Volume
- 2
- Issue
- 6
- Pages
- 904-908
- ISSN
- 2049-9450 (ISSN-L)
- 2049-9469
- OpenAlex
- W2105553762
- Cited by
- 435
- References
- 48
- FWCI
- 2.92
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.